COO Stock Declines Despite Strong Core Growth Amid Fertility Woes

The Cooper Companies (COO) demonstrated strong operational performance, with adjusted EPS up 14% and operating margin expanding to 24.9%, fueled by robust growth in its MyDay lenses and surgical devices. Despite this, the stock has underperformed, down 20.8% year-to-date, primarily due to slowing growth in its fertility segment, contact lens inventory destocking, and anticipated tariff and FX headwinds impacting the fiscal 2026 outlook. While strategic investments support long-term growth, investors must weigh COO's solid execution against these significant near-term macro and sector-specific uncertainties.

Analysis

The Cooper Companies (COO) is exhibiting a significant disconnect between strong operational performance and negative market sentiment, with its stock declining 20.8% year-to-date against the industry's 0.6% gain. Operationally, the company demonstrates resilience, delivering 14% year-over-year EPS growth and expanding its operating margin to 24.9% through disciplined cost management. This strength is driven by robust product performance, including 10% growth in MyDay lenses, 35% growth in MySight myopia products, and an 8% revenue increase in the CooperSurgical segment. However, this execution is being overshadowed by specific headwinds that are weighing on the stock. The fertility business has notably slowed to 3% growth, with management revising fiscal 2025 expectations down to low-single-digits due to weakness in Asia and deferred clinic spending. Furthermore, the company faces near-term pressure from contact lens inventory destocking across the channel. Looking ahead, forward guidance is clouded by a projected $4 million tariff impact on fiscal 2025 COGS and a potential 3% EPS headwind in fiscal 2026, creating uncertainty despite consensus estimates pointing to 10% EPS growth for fiscal 2025.

Key Decisions for Investors

• Investors should assess whether the 20.8% year-to-date share price decline adequately prices in the headwinds from the slowing fertility segment and inventory destocking, potentially creating a valuation opportunity if these issues are perceived as temporary.
• Monitor key data points in upcoming quarters, specifically fertility revenue trends in Asia and management commentary on the normalization of contact lens channel inventories, as these are the primary drivers of current negative sentiment.
• When modeling future earnings, it is crucial to incorporate the quantified fiscal 2025 tariff impact and the potential 3% EPS headwind in fiscal 2026, as these represent tangible risks to profitability not reflected in historical performance.
• Consider the company's diversification, where strength in the core vision and non-fertility surgical portfolios (up 13% in office-based devices) provides a partial buffer against the cyclical weakness in the fertility market.